EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Future Comorbidities in an Aging Cystic Fibrosis Population

Javier Humberto Ticona, Nicole Lapinel, Janice Wang

Life · 31.05.2023 · 13 (6) · 1305

DOI: 10.3390/life13061305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 31.05.2023. Verfasst von Javier Humberto Ticona und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is an autosomal recessive disease due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With the advent of highly effective modulator therapy targeting the abnormal CFTR protein, people with CF (PwCF) are living more than 40 years longer than the pre-modulator therapy era. As a result, PwCF are facing new challenges of managing similar comorbidities affecting the average aging population. While CF is notoriously identified as a chronic respiratory disease, the multisystem presence of the CFTR gene can contribute to other organ-related complications acutely, but also heighten the likelihood of chronic conditions not routinely encountered in this cohort. In this overview, we will focus on risk factors and epidemiology for PwCF as they relate to cardiovascular disease, dyslipidemia, CF-related diabetes, pulmonary hypertension, obstructive sleep apnea, CF-liver disease, bone health and malignancy. With increased awareness of diseases affecting a newly aging CF population, a focus on primary and secondary prevention will be imperative to implementing a comprehensive care plan to improve long-term morbidity and mortality.

Schlagwörter

Stichwörter der Autor:innen

cancercardiovascular diseasecystic-fibrosis liver disease (CFLD)cystic-fibrosis-related diabetes (CFRD)dyslipidemiahighly effective modulator therapy (HEMT)obstructive sleep apneaosteoporosispulmonary hypertensionscreening

Autor:innen und Institutionen

  • Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY 11042, USA.

Zitieren

APA

Ticona, J. H., Lapinel, N., & Wang, J. (2023). Future Comorbidities in an Aging Cystic Fibrosis Population. Life, 13(6), 1305. https://doi.org/10.3390/life13061305

Vancouver

Ticona JH, Lapinel N, Wang J. Future Comorbidities in an Aging Cystic Fibrosis Population. Life. 2023;13(6):1305. doi:10.3390/life13061305

BibTeX
@article{Ticona2023,
  author = {Ticona, Javier Humberto and Lapinel, Nicole and Wang, Janice},
  title = {Future Comorbidities in an Aging Cystic Fibrosis Population},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {6},
  pages = {1305},
  doi = {10.3390/life13061305}
}
Kostenlos starten →